Capricor Therapeutics, Inc. (CAPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$8.81+5.26%
Close 2026-09-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put CAPR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Obtain FDA approval for Deramiocel: PDUFA extended vs target end-2027.
View ThesisMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 3% on a typical day and fell roughly 89% in its worst 12-month stretch.
View RiskCAPR's success hinges on obtaining FDA approval for Deramiocel, which is currently pending. Revenue growth is uncertain, as the latest earnings report showed a miss with a -20.7% surprise. The stock trades at 12× price-to-sales, in line with the peer median of 11.9×. The primary risk is the FDA's potential delay in approval, which could extend the review period by three months. Peer multiples imply a price roughly in line with where it trades. Our read is provisional.
Trailing returns as of 2026-09-14. CAPR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering CAPR (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for CAPR in the last 4 months.
Continue this research
Compare CAPR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CAPR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CAPR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Address litigation with Nippon Shinyaku and NS Pharma
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $8.81
The last 12 months of price, then the range of analyst 12-month targets from today’s $8.81.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Litigation could hinder regulatory progress and cash sufficiency.
Threatens: Obtain FDA approval for Deramiocel for DMD treatment
FDA review extension delays potential approval for Deramiocel.
Board changes could disrupt management's strategic objectives.
Advances: Obtain FDA approval for Deramiocel for DMD treatment
FDA lifeline suggests progress towards Deramiocel approval.
Threatens: Address litigation with Nippon Shinyaku and NS Pharma
Class action scrutiny may complicate litigation resolution.
Advances: Seek FDA approval for Deramiocel
Potential FDA approval news boosts confidence in Deramiocel.
Threatens: Obtain FDA approval for Deramiocel for DMD treatment
FDA setback impacts approval timeline for Deramiocel.
Advances: Obtain FDA approval for Deramiocel for DMD treatment
FDA review signals progress towards Deramiocel approval.
